Core Viewpoint - The company Guichuang Tongqiao (02190.HK) has entered into an agreement to acquire a 49% stake in E-Med Solutions for approximately €18.375 million (around RMB 149 million), with options to acquire the remaining shares in the future [1][2]. Group 1: Acquisition Details - The acquisition agreement was signed on January 16, 2026, with the company acting as the buyer and E-Med Solutions as the seller [1]. - The total consideration for the acquisition is subject to further adjustments [1]. - The target company, Optimed Holding GmbH, is a limited liability company established under German law and is currently wholly owned by the seller [2]. Group 2: Target Company Overview - Optimed Holding GmbH and its subsidiaries, including Optimed Medizinische Instrumente GmbH, focus on the development, manufacturing, and distribution of medical technology products and solutions [2]. - The main operating subsidiary, Optimed Medizinische Instrumente GmbH, is headquartered in Germany and specializes in high-quality medical products for minimally invasive vascular and urological instruments [2]. - Optimed has a comprehensive product portfolio in the peripheral venous stent market, including devices for the iliac vein, iliac artery bifurcation, inferior vena cava, and aorta [2]. Group 3: Strategic Implications - Following the completion of the acquisition, the company and the target company will integrate their commercialization platforms, including sales and marketing networks, promotional capabilities, and customer service infrastructure [2]. - The target company will serve as the exclusive distributor for all vascular products outside of mainland China [2]. - Rüdiger Hausherr will continue as CEO of Optimed and report to Dr. Zhao Zhong, the company's chairman and CEO, which is expected to enhance and accelerate the company's international sales capabilities and global expansion [2].

Core Viewpoint - The company has entered into an agreement to acquire a 49% stake in Optimed Holding GmbH for approximately €18.375 million, marking a significant step in its global expansion strategy [1]. Group 1: Acquisition Details - The acquisition agreement allows the company to purchase 49% of Optimed Holding GmbH, with an option to acquire the remaining shares from other shareholders [1]. - Post-acquisition, Optimed will not become a subsidiary, and its financial performance will not be consolidated into the company's financial statements [1]. Group 2: Strategic Benefits - The acquisition represents a key milestone in the company's long-term commitment to global expansion, enhancing its competitive position and influence in international markets [1]. - Integration with Optimed's sales network will accelerate the global application of innovative vascular solutions, leveraging strong relationships with European medical experts [2]. - The transaction is expected to create significant manufacturing and operational synergies between Germany and China, improving product quality and operational efficiency [2]. - The company aims to fully leverage its R&D capabilities through an integrated global commercialization platform, providing advanced medical solutions to patients and healthcare professionals worldwide [2]. Group 3: Operational Integration - Following the acquisition, the company and Optimed will integrate their commercialization platforms, including sales and marketing networks, enhancing international sales capabilities [3]. - Optimed will serve as the exclusive distributor for all vascular products in markets outside of mainland China [3]. - Rüdiger Hausherr will continue as CEO of Optimed, reporting to the company's Chairman and CEO, Dr. Zhao Zhong, which will further accelerate the company's global expansion efforts [3].

Core Viewpoint - The acquisition of a 49% stake in Optimed Holding GmbH by the company marks a significant milestone in its long-term commitment to global expansion and aims to enhance its competitive position in the international market [1][2]. Group 1: Acquisition Details - The company has entered into a purchase agreement to acquire 49% of Optimed Holding GmbH for approximately €18.375 million [1]. - The agreement includes an option for the company to acquire the remaining shares from other shareholders at its discretion [1]. - Post-acquisition, Optimed will not become a subsidiary of the company, and its financial performance will not be consolidated into the company's financial statements [1]. Group 2: Strategic Benefits - The acquisition is a key milestone for the company's entry into the European and global markets, facilitating asset integration to accelerate international strategy deployment and diversify the product portfolio [2]. - The integration with Optimed's sales network will enhance the global application of innovative vascular solutions, leveraging strong relationships with European medical experts to expedite clinical processes and product launches [2]. - The transaction is expected to create significant manufacturing and operational synergies between Germany and China, improving product quality and operational efficiency while expanding production capacity in Germany [2]. Group 3: R&D and Commercialization - The integrated global commercialization platform will fully leverage the company's R&D capabilities, aiming to provide cutting-edge medical solutions to patients and healthcare professionals worldwide [3]. - Following the acquisition, the company and Optimed will integrate their commercialization platforms, including sales and marketing networks, enhancing international sales capabilities [3]. - Optimed will serve as the exclusive distributor for all vascular products in markets outside mainland China, with Rüdiger Hausherr continuing as CEO of Optimed [3].

Core Viewpoint - The company is set to acquire a 49% stake in Optimed Holding GmbH for approximately €18.375 million, marking a significant step in its global expansion strategy and enhancing its competitive position in the medical technology sector [1][2]. Group 1 - The acquisition represents a key milestone in the company's long-term commitment to global expansion, facilitating entry into European and global markets [2]. - The integration of assets is expected to accelerate the company's international strategy, diversify its product portfolio, and expand its global distribution network [2]. - The transaction aims to create significant manufacturing and operational synergies between Germany and China, enhancing product quality and operational efficiency [2]. Group 2 - The acquisition will enable the company to fully leverage its efficient R&D capabilities, expanding its innovative solutions to global markets [3]. - Post-acquisition, the company and Optimed will integrate their commercialization platforms, including sales and marketing networks, to enhance international sales capabilities [3]. - Optimed will serve as the exclusive distributor for all vascular products in markets outside of mainland China, significantly boosting the company's international sales efforts [3].

Zylox-Tonbridge Medical Technology Co., Ltd. 歸創通橋醫療科技股份有限公司 （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股份代號：2190） 須予披露交易 收購目標公司之49%股權 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 緒言 於 2026 年 1 月 16 日（交 易 時 段 前，香 港 時 間），本 公 司（作 為 買 方）與E-Med Solutions（作為賣方）訂立買賣協議。根據買賣協議，買方同意收購目標公司 之49%股權，總代價約為18.375百萬歐元（相當於人民幣149.41百萬元）（可予進 一步調整）。根據買賣協議，買方亦獲授期權，可由買方酌情行使，以向目 標公司其他股東收購目標公司之餘下股權。 建議收購事項完成後，目標公司將不會成為本公司之附屬公司，且目標公司 之財務業績將不會併入本公司之財務報表。 上市規則之涵義 由於有關買賣協議項下擬進 ...

Investment Rating - The report maintains an "Overweight" rating for the medical device industry [5]. Core Insights - The medical device industry in China has a prominent supply chain advantage, with overseas markets expected to maintain rapid growth. The brain-computer interface (BCI) sector is at a critical turning point, likely to see demand release. AI medical applications are gradually becoming operational, poised to reshape the health market [3]. Summary by Relevant Sections Investment Recommendations - For the overseas medical device sector, recommended stocks include: United Imaging Healthcare, Nanwei Medical, Microelectronic Physiology, Guichuang Tongqiao, Yuyue Medical, and New Industry. Stocks to watch include: Jingfeng Medical, MicroPort Scientific, and Chuangli Medical [5]. - In the brain-computer interface sector, recommended stocks are: Lepu Medical, Weisi Medical. Stocks to watch include: Meihao Medical, Xiangyu Medical, Mcland, Xinwei Medical, Aipeng Medical, Chengyitong, Chuangxin Medical, and Botuo Bio [5]. - For the AI + device sector, recommended stocks are: Yuyue Medical, BGI Genomics, KingMed Diagnostics, and United Imaging Healthcare. Stocks to watch include: Dian Diagnostics [5]. Overseas Market Growth - The supply chain advantage of domestic medical devices is significant, with exports expected to grow rapidly. In the first three quarters of 2025, United Imaging Healthcare's overseas revenue increased by 41.97% year-on-year, becoming a crucial growth driver for the company. The company continues to expand its market share in key regions due to superior product performance and localized service capabilities. By December 2025, MicroPort Scientific's global cumulative order volume exceeded 160 units, with core products in endoscopy, orthopedics, and vascular intervention surpassing 230 units in total orders. In 2025, Jingfeng Medical achieved a breakthrough in multiple key global markets, leading to explosive growth in overseas orders [5]. Brain-Computer Interface Market - The brain-computer interface market is at a pivotal turning point, with anticipated demand release. China's "14th Five-Year Plan" explicitly suggests a forward-looking layout for future industries, promoting BCI as a new economic growth point. In December 2025, Elon Musk announced that Neuralink would begin large-scale production of BCI devices in 2026, transitioning to a more streamlined and nearly fully automated surgical process. In January 2026, China's BCI company Strong Brain Technology announced it had completed a new round of financing of approximately 2 billion yuan, setting a record for the second-largest single financing in the field globally, following Neuralink. The funds will be used to accelerate core technology research and development, extreme engineering breakthroughs, and product scaling and mass production [5]. AI Medical Applications - AI medical applications are gradually becoming operational, with the potential to reshape the health market. In June 2025, Ant Group launched the AI Health Manager AQ, which was officially upgraded to "Antifufu" in December 2025. By January 2026, the "Antifufu" app had over 30 million monthly active users, with daily inquiries exceeding 10 million, 55% of which came from third-tier cities and below. In January 2026, Tempus AI reported preliminary revenue of approximately 1.27 billion USD for 2025, representing an 83% year-on-year increase, exceeding initial expectations. OpenAI announced the acquisition of the healthcare tech startup Torch to expand into the healthcare sector, while Google launched the next-generation open-source medical AI model MedGemma1.5 and released the open-source medical speech-to-text model MedASR [5].

Core Viewpoint - The centralized procurement of high-value medical consumables, specifically drug-coated balloons and urological intervention materials, is expected to standardize procurement and usage behaviors, improve industry ecology, and lead to short-term price declines impacting profit margins for some companies, while top domestic enterprises may gain market share through successful bids [1] Group 1: Event Overview - The national procurement office announced the results for centralized procurement of drug-coated balloons and urological intervention consumables, with implementation expected around May 2026 [1] Group 2: Selection Rate and Participation - A total of 227 companies submitted bids for 496 products, with 202 companies winning bids for 440 products, indicating a high overall selection rate which supports industry supply [2] - All 42 products from 32 companies in the drug-coated balloon category were selected, demonstrating a strong match with clinical usage [2] - In the urological intervention category, 170 out of 195 companies won bids for 398 products, including specialized products that meet specific clinical needs [2] Group 3: Performance of Listed Companies - Listed companies such as Lepu Medical, Bluestar Medical, and others achieved successful bids for various drug-coated balloons and urological intervention products, indicating a favorable selection outcome that may allow them to quickly expand their market share [3] Group 4: Procurement Rules and Principles - The procurement process reflects principles of "stabilizing clinical use, ensuring quality, countering internal competition, and preventing collusion," with a focus on maintaining clinical continuity and considering product functionality differences [4] - The selection rules are designed to prevent excessive price undercutting, with a mechanism in place to control price differences based on average bid prices, which has been effective in maintaining price stability [4] - The optimization of procurement rules indicates a maturing policy environment, with the "anti-involution" principle expected to be upheld in the long term [4]

Investment Rating - Buy: Expected industry growth exceeding 15% over the next 3-6 months [7] - Hold: Expected industry growth between -5% and 5% over the next 3-6 months [7] Core Insights - The centralized procurement of high-value medical consumables, including drug-coated balloons and urological intervention materials, is set to be implemented by May 2026, following the announcement of selected results [1] - A total of 12 types of medical consumables were included in the procurement, with a high selection rate among mainstream enterprises, ensuring supply stability in the industry [2] - Domestic listed companies performed well in the selection process, with several products selected at competitive prices, indicating potential for rapid market share expansion [3] - The procurement rules reflect principles aimed at stabilizing clinical use, ensuring quality, and preventing price undercutting, which is expected to mature over time [4] - The implementation of this procurement is likely to standardize purchasing behaviors and improve the industry ecosystem, although short-term price declines may impact profit margins for some companies [5]

Core Insights - The sixth batch of national high-value medical consumables procurement results was released, including 12 types of medical consumables from two categories: drug-coated balloons and urological intervention products [1] - A total of 227 companies submitted bids for 496 products, with 202 companies winning bids for 440 products [1] - The procurement aims to reduce prices and improve market access for medical consumables, with significant price reductions expected [5][8] Group 1: Procurement Details - The procurement includes drug-coated balloons, which are used to treat vascular stenosis, and urological intervention consumables for kidney stone surgeries [1] - All 42 products from 32 companies in the drug-coated balloon category were selected, while 398 products from 170 companies in the urological intervention category were chosen [1] - The overall price reduction has not been officially disclosed, but estimates suggest significant decreases based on winning bid data [5] Group 2: New Procurement Mechanisms - The procurement introduced a "reference price" concept to prevent extreme low bidding, setting a baseline at 65% of the average bid price [2][3] - Two revival mechanisms were established, allowing companies that did not win bids to re-compete in subsequent rounds [4] Group 3: Market Impact and Company Insights - Companies like Lepu Medical and Weili Medical won multiple bids, with Lepu's drug-coated balloons seeing price reductions of approximately 52.18% to 64.68% compared to previous prices [6][7] - Weili Medical anticipates a price drop of 60% to 80% for its products, which could reshape the market for drug-coated balloons and urological intervention consumables, previously valued at around 11 billion yuan [7][8] - The procurement process is expected to streamline market access for companies, reducing reliance on intermediaries and ensuring direct hospital access [8]

Market Review - The CITIC Medical Index increased by 7.70%, outperforming the CSI 300 Index by 4.91 percentage points, ranking 5th among 30 primary industries [8] - The top ten stocks by increase this week include: Bibet-U, Innovation Medical, Sanbo Brain Science, and others, with significant gains [8] - The top ten stocks by decrease include: Baihua Medicine, Jinhao Medical, and others, with notable declines [8] Overall View and Investment Themes - The domestic innovative drug industry is transitioning from quantity logic to quality logic, focusing on differentiated and internationalized pipelines, with an emphasis on products that can generate profits by 2025 [11] - In the medical device sector, there is a noticeable recovery in bidding volumes for imaging equipment, with ongoing updates and acceleration in overseas expansion [11] - The innovative chain (CXO + life science services) is expected to see a rebound in overseas investment, with domestic investment stabilizing, indicating a potential bottoming out [11] - The pharmaceutical industry is anticipated to enter a new growth cycle, with cost improvements in specialty raw materials and a focus on patent expirations leading to new growth opportunities [11] Traditional Chinese Medicine - The basic drug directory is expected to be released, with unique basic drugs projected to grow faster than non-basic drugs, indicating a potential market rebound [12] - The reform of state-owned enterprises is expected to enhance the fundamental performance of companies, particularly after adjustments to the evaluation system [12] - The new medical insurance directory is expected to benefit certain companies, with a focus on OTC enterprises that cater to aging populations and have strong dividend characteristics [12] Medical Services - The anti-corruption and centralized procurement efforts are expected to purify the medical market environment, enhancing the competitiveness of private medical services [12] - The rapid expansion of commercial insurance and self-funded medical services is likely to provide more competitive advantages for private healthcare providers [12] Blood Products - The approval of plasma stations is expected to increase supply, with companies expanding their product offerings and production capacity, indicating a clear long-term growth path for the blood products industry [12]